EMMA

European Multiple Myeloma Academy

34th EMMA / Post-IMS & ASH 2026 meetings | 2027

Friday 12th - Saturday 13th, February 2027
Madrid, Spain

In-person meeting INNSiDE Madrid Valdebebas Hotel

Chairs:
Dr. Jesús F. San-Miguel, Clínica Universidad de Navarra, Pamplona (Spain)
Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna (Austria)
Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona (Spain)

Organized by:

Universidad de Navarra

Friday, February 12th

08:45 - 09:00 **Opening**
Dr. Jesús San Miguel, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria
Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

09:00 - 10:40 **PLENARY SESSION 1**

DIAGNOSTIC TOOLS in 2027: Prognostication & Monitoring

Moderator: Dr. Jesús San Miguel, Clínica Universidad de Navarra, Pamplona, Spain

09:00 - 09:20 **Genomics: from MGUS to MM?**
Dr. Anaïs Schavgoulidze, Centre de Recherches en Cancérologie de Toulouse (CRCT), Toulouse, France

09:20 - 09:40 **Inmunophenotyping: MRD, CTC, inmune monitoring....?**
Dr. Bruno Paiva, CIMA, Clínica Universidad de Navarra, Pamplona, Spain

09:40 - 10:00 **Protein evaluation: from electrophoresis to Mass Spectometry?**
Dr. Noemi Puig, Hospital Universitario de Salamanca, IBSAL, Spain

10:00 - 10:20 **Imaging: CT? PET? MRI?**
Dr. Elena Zamagni, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute, Italy

10:20 - 10:40 **Experts' discussion & burning questions:**

1. **FISH vs NGS? Gemomics in SMM? At relapse?**
2. **MRD and CTC in routine practice?**
3. **Should we more to MS?**
4. **How to monitor some disease?**

Discussants:

Dr. Felipe Prósper, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Bruno Paiva, CIMA, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Noemi Puig, Hospital Universitario de Salamanca, IBSAL, Spain
Dr. Elena Zamagni, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Seràgnoli Institute, Italy
Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain

Friday, February 12th

10:40 - 11:35 **PLENARY SESSION 2**
PRECURSORS CONDITIONS

Moderator: Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria

10:40 - 11:00 **What should I know about systemic manifestations in MGUS patients?**
Dr. Joan Bladé, Hospital Clínic de Barcelona, IDIBAPS, Spain

11:00 - 11:20 **Can we identify and treat high risk Smoldering Myeloma patients?**
Dr. María Victoria Mateos, Hospital Universitario de Salamanca, IBSAL, Spain

11:20 - 11:35 **Experts' discussion around 5 burning questions:**

1. When to atribute clinical manifestations to the M-component?
2. Optimal treatment in MGUS with renal impairment
3. How to define High Risk SMM?
4. To treat or no to treat SMM and how

Discussants:

Dr. Joan Bladé, Hospital Clínic de Barcelona, IDIBAPS, Spain
Dr. María Victoria Mateos, Hospital Universitario de Salamanca, IBSAL, Spain
Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria
Dr. Kew Young, University College London (UCL), United Kingdom

11:35 - 11:55 **BREAK**

11:55 - 13:15 **PLENARY SESSION 3**
CHALLENGING TOPICS

Moderator: Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain

11:55 - 12:15 **1. Emergencies and supportive care (cord compression, RI, bone disease)**
Dr. Evangelos Terpos, National and Kapodistrian University of Athens, Alexandra Hospital, Greece

12:15 - 12:35 **2. What are the clues for difficult to treat MM (extramedullary, CNS, solitary)?**
Dr. Kew Young, University College London (UCL), United Kingdom

12:35 - 12:55 **3. How to deal with immunotherpy adverse events**
Dr. Niels van de Donk, Amsterdam UMC, Vrije Universiteit Amsterdam, The Netherlands

12:55 - 13:15 **Questions & discussion**

13:15 - 14:00 **LUNCH**

Friday, February 12th

14:00 - 14:30 **PLENARY SESSION 4**

KEYNOTE LECTURE

Moderator: Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

14:00 - 14:20 **How to prevent and treat infections in myeloma**
Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria

14:20 - 14:30 **Questions & discussion**

14:30 - 14:50 **BREAK**

14:50 - 16:10 **PLENARY SESSION 5**

FRONT LINE TREATMENT FOR YOUNG PATIENTS WITH MM

Moderator: Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

14:50 - 15:10 **Is there an optimal induction? Transplant for all?**
Prof. Cyrille Touzeau, University Hospital of Nantes, Nantes, France

15:10 - 15:30 **What type of consolidation and maintenance is recommended?**
Dr. Francesca Gay, AOU Città della Salute e della Scienza, University of Torino, Italy

15:30 - 15:50 **How to approach high-risk patients?**
Dr. Elias Mai, University Hospital Heidelberg,Germany

15:50 - 16:10 **Experts' discussion on 7 burning topics:**

1. **Best induction**
2. **Early vs. late transplant**
3. **One vs. two**
4. **Consolidation & maintenance**
5. **High risk**

Discussants:

Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Elias Mai, University Hospital Heidelberg,Germany
Dr. Francesca Gay, AOU Città della Salute e della Scienza, University of Torino, Italy
Dr. Kew Young, University College London (UCL), United Kingdom
Dr. Joan Bladé, Hospital Clínic de Barcelona, IDIBAPS, Spain

16:10 - 16:30 **BREAK**

Friday, February 12th

16:30 - 17:25

PLENARY SESSION 6

FRONT LINE TREATMENT FOR ELDERLY PATIENTS WITH MM

Moderator: Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria

16:30 - 16:50 **How should I treat elderly patients?**
Dr. Salomon Manier, CHU de Lille, University of Lille, France

16:50 - 17:10 **How should I treat elderly frail patients?**
Prof. Alessandra Larocca, University of Turin, Turin, Italy

17:10 - 17:25 **Experts' discussion on 5 burning topics:**

1. **Optimal combination and duration**
2. **Maintenance/continuous**
3. **Do we need alkylators?**
4. **High risk**
5. **Frailty**

Discussants:

Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria
Dr. Salomon Manier, CHU de Lille, University of Lille, France
Prof. Alessandra Larocca, University of Turin, Turin, Italy.
Dr. María Victoria Mateos, Hospital Universitario de Salamanca, IBSAL, Spain

Saturday, February 13th

09:00 - 10:40 **PLENARY SESSION 7**

MANAGEMENT OF THE RELAPSED PATIENT

09:00 - 09:20 **How should I treat relapsed patients (with approved drugs)?**
Dr. Enrique Ocio, Hospital Universitario Marqués de Valdecilla, Santander, Spain

09:20 - 09:40 **Bispecific and ADC : When and how?**
Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

09:40 - 10:00 **CAR-T cells and other adoptive therapies: When and how?**
Dr. Hermann Einsele, Universitätsklinikum Würzburg, Germany

10:00 - 10:20 **Are new pathways to be targeted in Myeloma?**
Dra. Chalotte Pawlin, The Institute of Cancer Research & The Royal Marsden, London, United Kingdom

10:20 - 10:40 **Experts' discussion on 5 burning topics:**

1. **Biological relapse versus aggressive relapse**
2. **Triplet versus doublets: is it cost-effective?**
3. **Is CAR-T the future? alone or combined with anti-MM drugs?**
4. **Bispecific antibodies or CAR-T**
5. **Industry or academia**

Discussants:

Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Hermann Einsele, Universitätsklinikum Würzburg, Germany
Dr. Enrique Ocio, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Dr. Efstathios Kastritis, National and Kapodistrian University of Athens, Alexandra Hospital, Greece

10:40 - 11:00 **BREAK**

11:00 - 11:40 **PLENARY SESSION 8**

HOW I TREAT OTHER MALIGNANT GAMMOPATHIES

Moderator:
Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain
Dr. Heinz Ludwig, Wilhelminen Cancer Research Institute, Vienna, Austria
Dr. Paula Rodríguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

11:40 - 12:00 **EHA-2025 Guidelines: How can help me in my daily practice**
Dr. Pieter Sonneveld, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

12:00 - 12:15 **Questions & discussion**

12:15 - 12:25 **CLOSING REMARKS**
Dr. Jesús F. San Miguel, Clínica Universidad de Navarra, Pamplona, Spain

Venue

INNSiDE Madrid Valdebebas Hotel
C. de José Antonio Fernández Ordóñez, 55
Hortaleza, 28055 Madrid, Spain

This meeting is targeted towards myeloma treating physicians who are interested in understanding and discussing the latest developments in myeloma diagnosis and treatment.



Campus Universidad de Navarra

This meeting is organized and hosted by Professor Jesús F. San-Miguel, Clínica Universidad de Navarra, Pamplona (Spain).

www.emma-madrid.com

HEALTH COMMUNICATION
DOCTA FORUM

Scientific Secretariat
Tel.:(+34) 670 95 75 48
e-mail: emma@doctaforum.com
www.emma-madrid.com

Organized by:

Universidad de Navarra